SRR608368
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.455
- TNFA_SIGNALING_VIA_NFKB+0.443
- ANGIOGENESIS+0.409
- IL6_JAK_STAT3_SIGNALING+0.362
- APICAL_SURFACE+0.344
- HEDGEHOG_SIGNALING+0.333
- INFLAMMATORY_RESPONSE+0.327
- INTERFERON_GAMMA_RESPONSE+0.314
- COAGULATION+0.309
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.266
Top 10 suppressed
- MYC_TARGETS_V1-0.564
- PROTEIN_SECRETION-0.508
- DNA_REPAIR-0.494
- E2F_TARGETS-0.419
- MYC_TARGETS_V2-0.383
- MTORC1_SIGNALING-0.368
- G2M_CHECKPOINT-0.366
- UNFOLDED_PROTEIN_RESPONSE-0.365
- OXIDATIVE_PHOSPHORYLATION-0.351
- NOTCH_SIGNALING-0.293
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR603752 | GTEX | — | 0.968 |
| 2 | SRR1322456 | GTEX | — | 0.935 |
| 3 | SJEPD001535_R2.RNA-Seq | EPN | Posterior Fossa EPN | 0.929 |
| 4 | SRR1391598 | GTEX | — | 0.928 |
| 5 | SRR604528 | GTEX | — | 0.928 |
| 6 | SRR1418283 | GTEX | — | 0.927 |
| 7 | SRR1317494 | GTEX | — | 0.926 |
| 8 | BS_2SHWPB5P | ganglioneuroblastoma | — | 0.921 |
| 9 | SRR602271 | GTEX | — | 0.920 |
| 10 | MDT-AP-0746 | Med | Medulloblastoma | 0.917 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.455 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.443 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.409 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.362 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.344 | Temsirolimus | — uncovered |
| HEDGEHOG_SIGNALING | 0.333 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.327 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.314 | Idelalisib | — uncovered |
| COAGULATION | 0.309 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.266 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.236 | Inavolisib | — uncovered |
| MYOGENESIS | 0.195 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.185 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.164 | Idelalisib | — uncovered |
| COMPLEMENT | 0.163 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.155 | Inavolisib | — uncovered |
| APOPTOSIS | 0.152 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.145 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.144 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.143 | Idelalisib | — uncovered |